ScholarIQanswers from OpenAlex

Cetuximab Combined with Vemurafenib Can Significantly Inhibit the Proli- Feration Of Braf V600e Mutant Egfr Wild-Type Colorectal Cancer Cells

PaperCitations, authors & open-access status

Cetuximab Combined with Vemurafenib Can Significantly Inhibit the Proli- Feration Of Braf V600e Mutant Egfr Wild-Type Colorectal Cancer Cells is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Cetuximab Combined with Vemurafenib Can Significantly Inhibit the Proli- Feration Of Braf V600e Mutant Egfr Wild-Type Colorectal Cancer Cells have?

ScholarIQcitation count

Cetuximab Combined with Vemurafenib Can Significantly Inhibit the Proli- Feration Of Braf V600e Mutant Egfr Wild-Type Colorectal Cancer Cells has 0 citations in the OpenAlex counts ScholarIQ stores.

When was Cetuximab Combined with Vemurafenib Can Significantly Inhibit the Proli- Feration Of Braf V600e Mutant Egfr Wild-Type Colorectal Cancer Cells published?

ScholarIQyear

Cetuximab Combined with Vemurafenib Can Significantly Inhibit the Proli- Feration Of Braf V600e Mutant Egfr Wild-Type Colorectal Cancer Cells has 2020 year in the ScholarIQ index.

What is the open-access status of Cetuximab Combined with Vemurafenib Can Significantly Inhibit the Proli- Feration Of Braf V600e Mutant Egfr Wild-Type Colorectal Cancer Cells?

ScholarIQoa status

Cetuximab Combined with Vemurafenib Can Significantly Inhibit the Proli- Feration Of Braf V600e Mutant Egfr Wild-Type Colorectal Cancer Cells has closed oa status in the ScholarIQ index.

What is the DOI of Cetuximab Combined with Vemurafenib Can Significantly Inhibit the Proli- Feration Of Braf V600e Mutant Egfr Wild-Type Colorectal Cancer Cells?

ScholarIQdoi

The DOI for Cetuximab Combined with Vemurafenib Can Significantly Inhibit the Proli- Feration Of Braf V600e Mutant Egfr Wild-Type Colorectal Cancer Cells is on the source record.

What is the OpenAlex record for Cetuximab Combined with Vemurafenib Can Significantly Inhibit the Proli- Feration Of Braf V600e Mutant Egfr Wild-Type Colorectal Cancer Cells?

ScholarIQopenalex

The OpenAlex for Cetuximab Combined with Vemurafenib Can Significantly Inhibit the Proli- Feration Of Braf V600e Mutant Egfr Wild-Type Colorectal Cancer Cells is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial